Company: VERA
Filing Date: 2025-04-03
Form Type: DEF 14A
Source: 0001140361-25-012034
Chunk: 34

Company: Vera Therapeutics, Inc.
Filing Date: 2025-04-03
Form: DEF 14A
Chunk 34
---
1. Mr. Grant previously served as Vice President of Corporate Strategy and Business Development for CareDx, Inc., a biotechnology company, from May 2020 to June 2021. His responsibilities included leading mergers and acquisitions, venture investments and partnerships across diagnostics and therapeutics. Prior to joining CareDx, Mr. Grant served as Vice President in the Investment Banking Healthcare Division at Citigroup Global Capital Markets from July 2015 to March 2020. At Citigroup, Mr. Grant specialized in public and private capital raising as well as mergers and acquisitions for leading life science companies. Mr. Grant received a B.A. in Government and International Politics from George Mason University and an M.B.A. from the Johns Hopkins University Carey Business School. Jason Carter has served as our Chief Legal Officer since November 2024. Mr. Carter recently served as Global Head of Legal & General Counsel of Kite Pharma, Inc. (a biopharmaceutical company acquired by Gilead), a position he held from June 2020 to December 2023, where he led the global legal and compliance functions. Mr. Carter served as an Assistant General Counsel for Daiichi Sankyo, Company, Limited, a biopharmaceutical company, from November 2017 to May 2020, where he supported the oncology research and development department and the global antibody drug conjugate. Prior to that, Mr. Carter worked as a consultant for a number of different biopharmaceutical companies. Before his time as a consultant, he worked as General Counsel for G&W Laboratories, Inc. and as Global Head of Legal Transactions, Rare Diseases and Immunology for Novartis A.G. Mr. Carter received his B.A. from Temple University and his J.D. from the University of Wisconsin – Madison Law School. David Johnson has served as our Chief Operating Officer since July 2024. He previously served as Chief Commercial Officer of Global Blood Therapeutics (a biotechnology company acquired by Pfizer Inc.), a position he held from March 2018 to December 2022, where he led the global commercial functions and facilitated the launch of Oxbryta ®in 2019. Previously, Mr. Johnson was employed by Gilead from 2003 to 2018, where he held roles of increasing responsibility in the company’s commercial organization, including as vice president, sales and marketing, Liver Disease Business Unit, where he was instrumental in building and leading Gilead’s liver disease franchise, including launching four medicines